+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Anorexia Nervosa Market by Treatment Type, Age Group, Severity Level, End User, Treatment Channel - Global Forecast 2025-2030- Product Image
Anorexia Nervosa Market by Treatment Type, Age Group, Severity Level, End User, Treatment Channel - Global Forecast 2025-2030- Product Image
Sale

Anorexia Nervosa Market by Treatment Type, Age Group, Severity Level, End User, Treatment Channel - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 194 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 6015168
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Anorexia Nervosa Market grew from USD 94.65 million in 2023 to USD 106.87 million in 2024. It is expected to continue growing at a CAGR of 13.27%, reaching USD 226.52 million by 2030.

Anorexia Nervosa (AN) is a severe mental health disorder characterized by an intense fear of weight gain, leading to restricted food intake, emaciation, and potential physiological damage. It primarily affects adolescents and young adults, particularly females, with increasing incidence in males. Market necessity revolves around early diagnosis, effective therapeutic options, and supportive interventions to manage this life-threatening condition. Applications span across medical diagnostics, behavioral therapy, pharmaceuticals, and nutritional products. End-use primarily involves clinics, hospitals, research institutions, and rehabilitation centers which address both medical and psychological aspects of the disorder.

Market growth is influenced by increasing awareness, technological advancements in diagnostics, and improved health infrastructure. Emerging opportunities lie in developing personalized medicine, leveraging AI for predictive analytics, and extending teletherapy platforms. Companies can capitalize on these areas by investing in multidisciplinary research efforts to innovate nutritional supplements or novel pharmaceuticals that provide quicker recovery with fewer side effects. Collaborations with mental health tech startups can offer comprehensive care via digital solutions, catering to remote areas with limited access to specialized care.

Challenges include the stigma associated with psychiatric disorders, particularly in conservative regions, which limits patient outreach. Additionally, the regulatory environment for mental health medications remains stringent, potentially delaying the introduction of new treatments. Another challenge is the high cost of comprehensive care, including psychotherapy and hospitalization, which limits affordability in underinsured populations.

Innovation can thrive through the development of integrative care approaches combining artificial intelligence with cognitive-behavioral therapies, and through pioneering holistic dietary programs that support mental and physical recovery. The market's nature is evolving, with increased emphasis on mental health parity. Thus, stakeholders must focus on educational campaigns to destigmatize psychiatric care, streamline regulatory processes for faster drug approval, and boost public-private partnerships to improve treatment affordability and accessibility. Such proactive approaches can enhance market resilience and spur business growth in the anorexia treatment landscape.

Understanding Market Dynamics in the Anorexia Nervosa Market

The Anorexia Nervosa Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Expanding role of online and digital therapies in treating patients with Anorexia Nervosa
    • Government initiatives and funding for mental health research and treatment programs
    • Integration of multidisciplinary approaches involving nutritionists, psychologists, and medical doctors for comprehensive patient care
  • Market Restraints
    • High stigma and lack of awareness surrounding anorexia nervosa impede early diagnosis and intervention
  • Market Opportunities
    • Leveraging artificial intelligence to improve early detection and diagnosis of anorexia nervosa
    • Developing targeted nutritional programs to support recovery in anorexia nervosa patients
  • Market Challenges
    • Limited effective treatment options for anorexia nervosa hinder widespread recovery

Exploring Porter’s Five Forces for the Anorexia Nervosa Market

Porter’s Five Forces framework further strengthens the insights of the Anorexia Nervosa Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Anorexia Nervosa Market

External macro-environmental factors deeply influence the performance of the Anorexia Nervosa Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Anorexia Nervosa Market

The Anorexia Nervosa Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Anorexia Nervosa Market

The Anorexia Nervosa Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Anorexia Nervosa Market

The Anorexia Nervosa Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Anorexia Nervosa Market, highlighting leading vendors and their innovative profiles. These include Alkermes plc, Amgen Inc., Biohaven Pharmaceuticals, Hologic, Inc., Johnson & Johnson, Merck & Co., Inc., Mindstrong Health, Otsuka Pharmaceutical Co., Ltd., Pfizer Inc., PsychoGenics Inc., Sanofi S.A., Sumitomo Pharma America, Inc., Takeda Pharmaceutical Company Limited., and Tonix Pharmaceuticals Holding Corp..

Market Segmentation & Coverage

This research report categorizes the Anorexia Nervosa Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Treatment Type
    • Nutritional Counseling
    • Pharmacotherapy
      • Antidepressants
      • Antipsychotics
      • Mood Stabilizers
    • Psychotherapy
      • Cognitive Behavioral Therapy
      • Family-Based Therapy
      • Interpersonal Psychotherapy
  • Age Group
    • Adults
    • Children & Adolescents
  • Severity Level
    • Mild
    • Moderate
    • Severe
  • End User
    • Clinics
    • Homecare
    • Hospitals
  • Treatment Channel
    • In-Patient
    • Out-Patient
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Expanding role of online and digital therapies in treating patients with Anorexia Nervosa
5.1.1.2. Government initiatives and funding for mental health research and treatment programs
5.1.1.3. Integration of multidisciplinary approaches involving nutritionists, psychologists, and medical doctors for comprehensive patient care
5.1.2. Restraints
5.1.2.1. High stigma and lack of awareness surrounding anorexia nervosa impede early diagnosis and intervention
5.1.3. Opportunities
5.1.3.1. Leveraging artificial intelligence to improve early detection and diagnosis of anorexia nervosa
5.1.3.2. Developing targeted nutritional programs to support recovery in anorexia nervosa patients
5.1.4. Challenges
5.1.4.1. Limited effective treatment options for anorexia nervosa hinder widespread recovery
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Anorexia Nervosa Market, by Treatment Type
6.1. Introduction
6.2. Nutritional Counseling
6.3. Pharmacotherapy
6.3.1. Antidepressants
6.3.2. Antipsychotics
6.3.3. Mood Stabilizers
6.4. Psychotherapy
6.4.1. Cognitive Behavioral Therapy
6.4.2. Family-Based Therapy
6.4.3. Interpersonal Psychotherapy
7. Anorexia Nervosa Market, by Age Group
7.1. Introduction
7.2. Adults
7.3. Children & Adolescents
8. Anorexia Nervosa Market, by Severity Level
8.1. Introduction
8.2. Mild
8.3. Moderate
8.4. Severe
9. Anorexia Nervosa Market, by End User
9.1. Introduction
9.2. Clinics
9.3. Homecare
9.4. Hospitals
10. Anorexia Nervosa Market, by Treatment Channel
10.1. Introduction
10.2. In-Patient
10.3. Out-Patient
11. Americas Anorexia Nervosa Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific Anorexia Nervosa Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam
13. Europe, Middle East & Africa Anorexia Nervosa Market
13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom
14. Competitive Landscape
14.1. Market Share Analysis, 2023
14.2. FPNV Positioning Matrix, 2023
14.3. Competitive Scenario Analysis
14.3.1. A new EUR 2.7 million research initiative explores eating disorders, self-harm, and autism links to improve early diagnosis and interventions among youth
14.3.2. Equip secures additional funding to expand virtual eating disorder treatment services
14.3.3. UC San Diego launches clinical trial with USD 235,000 donation to explore ketogenic therapy effectiveness on anorexia nervosa relapse prevention
14.4. Strategy Analysis & Recommendation
14.4.1. Merck & Co., Inc.
List of Figures
FIGURE 1. ANOREXIA NERVOSA MARKET RESEARCH PROCESS
FIGURE 2. ANOREXIA NERVOSA MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL ANOREXIA NERVOSA MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
FIGURE 7. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2023 VS 2030 (%)
FIGURE 9. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2023 VS 2030 (%)
FIGURE 11. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2023 VS 2030 (%)
FIGURE 13. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2023 VS 2030 (%)
FIGURE 15. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 17. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. UNITED STATES ANOREXIA NERVOSA MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 19. UNITED STATES ANOREXIA NERVOSA MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 21. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 24. ANOREXIA NERVOSA MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 25. ANOREXIA NERVOSA MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. ANOREXIA NERVOSA MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL ANOREXIA NERVOSA MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. ANOREXIA NERVOSA MARKET DYNAMICS
TABLE 7. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY NUTRITIONAL COUNSELING, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY ANTIDEPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY ANTIPSYCHOTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY MOOD STABILIZERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY COGNITIVE BEHAVIORAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY FAMILY-BASED THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY INTERPERSONAL PSYCHOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY CHILDREN & ADOLESCENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY MILD, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY MODERATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY SEVERE, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY IN-PATIENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY OUT-PATIENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 41. ARGENTINA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 42. ARGENTINA ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 43. ARGENTINA ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
TABLE 44. ARGENTINA ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 45. ARGENTINA ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
TABLE 46. ARGENTINA ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 47. ARGENTINA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
TABLE 48. BRAZIL ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 49. BRAZIL ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 50. BRAZIL ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
TABLE 51. BRAZIL ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 52. BRAZIL ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
TABLE 53. BRAZIL ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 54. BRAZIL ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
TABLE 55. CANADA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 56. CANADA ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 57. CANADA ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
TABLE 58. CANADA ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 59. CANADA ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
TABLE 60. CANADA ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 61. CANADA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
TABLE 62. MEXICO ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 63. MEXICO ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 64. MEXICO ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
TABLE 65. MEXICO ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 66. MEXICO ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
TABLE 67. MEXICO ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 68. MEXICO ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 70. UNITED STATES ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 71. UNITED STATES ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
TABLE 72. UNITED STATES ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 73. UNITED STATES ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
TABLE 74. UNITED STATES ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 75. UNITED STATES ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
TABLE 76. UNITED STATES ANOREXIA NERVOSA MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 77. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 78. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 79. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
TABLE 80. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 81. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
TABLE 82. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 83. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
TABLE 84. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 85. AUSTRALIA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 86. AUSTRALIA ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 87. AUSTRALIA ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
TABLE 88. AUSTRALIA ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 89. AUSTRALIA ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
TABLE 90. AUSTRALIA ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 91. AUSTRALIA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
TABLE 92. CHINA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 93. CHINA ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 94. CHINA ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
TABLE 95. CHINA ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 96. CHINA ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
TABLE 97. CHINA ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 98. CHINA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
TABLE 99. INDIA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 100. INDIA ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 101. INDIA ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
TABLE 102. INDIA ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 103. INDIA ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
TABLE 104. INDIA ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 105. INDIA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
TABLE 106. INDONESIA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 107. INDONESIA ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 108. INDONESIA ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
TABLE 109. INDONESIA ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 110. INDONESIA ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
TABLE 111. INDONESIA ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 112. INDONESIA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
TABLE 113. JAPAN ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 114. JAPAN ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 115. JAPAN ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
TABLE 116. JAPAN ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 117. JAPAN ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
TABLE 118. JAPAN ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 119. JAPAN ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
TABLE 120. MALAYSIA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 121. MALAYSIA ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 122. MALAYSIA ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
TABLE 123. MALAYSIA ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 124. MALAYSIA ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
TABLE 125. MALAYSIA ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 126. MALAYSIA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
TABLE 127. PHILIPPINES ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 128. PHILIPPINES ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 129. PHILIPPINES ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
TABLE 130. PHILIPPINES ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 131. PHILIPPINES ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
TABLE 132. PHILIPPINES ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 133. PHILIPPINES ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
TABLE 134. SINGAPORE ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 135. SINGAPORE ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 136. SINGAPORE ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
TABLE 137. SINGAPORE ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 138. SINGAPORE ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
TABLE 139. SINGAPORE ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 140. SINGAPORE ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
TABLE 141. SOUTH KOREA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 142. SOUTH KOREA ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 143. SOUTH KOREA ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
TABLE 144. SOUTH KOREA ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 145. SOUTH KOREA ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
TABLE 146. SOUTH KOREA ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 147. SOUTH KOREA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
TABLE 148. TAIWAN ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 149. TAIWAN ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 150. TAIWAN ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
TABLE 151. TAIWAN ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 152. TAIWAN ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
TABLE 153. TAIWAN ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 154. TAIWAN ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
TABLE 155. THAILAND ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 156. THAILAND ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 157. THAILAND ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
TABLE 158. THAILAND ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 159. THAILAND ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
TABLE 160. THAILAND ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 161. THAILAND ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
TABLE 162. VIETNAM ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 163. VIETNAM ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 164. VIETNAM ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
TABLE 165. VIETNAM ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 166. VIETNAM ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
TABLE 167. VIETNAM ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 168. VIETNAM ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
TABLE 169. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 170. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 171. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
TABLE 172. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 173. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
TABLE 174. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 175. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
TABLE 176. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 177. DENMARK ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 178. DENMARK ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 179. DENMARK ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
TABLE 180. DENMARK ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 181. DENMARK ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
TABLE 182. DENMARK ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 183. DENMARK ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
TABLE 184. EGYPT ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 185. EGYPT ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 186. EGYPT ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
TABLE 187. EGYPT ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 188. EGYPT ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
TABLE 189. EGYPT ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 190. EGYPT ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
TABLE 191. FINLAND ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 192. FINLAND ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 193. FINLAND ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
TABLE 194. FINLAND ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 195. FINLAND ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
TABLE 196. FINLAND ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 197. FINLAND ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
TABLE 198. FRANCE ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 199. FRANCE ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 200. FRANCE ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
TABLE 201. FRANCE ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 202. FRANCE ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
TABLE 203. FRANCE ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 204. FRANCE ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
TABLE 205. GERMANY ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 206. GERMANY ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 207. GERMANY ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
TABLE 208. GERMANY ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 209. GERMANY ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
TABLE 210. GERMANY ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 211. GERMANY ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
TABLE 212. ISRAEL ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 213. ISRAEL ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 214. ISRAEL ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
TABLE 215. ISRAEL ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 216. ISRAEL ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
TABLE 217. ISRAEL ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 218. ISRAEL ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
TABLE 219. ITALY ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 220. ITALY ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 221. ITALY ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
TABLE 222. ITALY ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 223. ITALY ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
TABLE 224. ITALY ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 225. ITALY ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
TABLE 226. NETHERLANDS ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 227. NETHERLANDS ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 228. NETHERLANDS ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
TABLE 229. NETHERLANDS ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 230. NETHERLANDS ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
TABLE 231. NETHERLANDS ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 232. NETHERLANDS ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
TABLE 233. NIGERIA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 234. NIGERIA ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 235. NIGERIA ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
TABLE 236. NIGERIA ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 237. NIGERIA ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
TABLE 238. NIGERIA ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 239. NIGERIA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
TABLE 240. NORWAY ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 241. NORWAY ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 242. NORWAY ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
TABLE 243. NORWAY ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 244. NORWAY ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
TABLE 245. NORWAY ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 246. NORWAY ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
TABLE 247. POLAND ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 248. POLAND ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 249. POLAND ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
TABLE 250. POLAND ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 251. POLAND ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
TABLE 252. POLAND ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 253. POLAND ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
TABLE 254. QATAR ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 255. QATAR ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 256. QATAR ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
TABLE 257. QATAR ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 258. QATAR ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
TABLE 259. QATAR ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 260. QATAR ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
TABLE 261. RUSSIA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 262. RUSSIA ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 263. RUSSIA ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
TABLE 264. RUSSIA ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 265. RUSSIA ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
TABLE 266. RUSSIA ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 267. RUSSIA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
TABLE 268. SAUDI ARABIA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 269. SAUDI ARABIA ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 270. SAUDI ARABIA ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
TABLE 271. SAUDI ARABIA ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 272. SAUDI ARABIA ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
TABLE 273. SAUDI ARABIA ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 274. SAUDI ARABIA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
TABLE 275. SOUTH AFRICA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 276. SOUTH AFRICA ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 277. SOUTH AFRICA ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
TABLE 278. SOUTH AFRICA ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 279. SOUTH AFRICA ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
TABLE 280. SOUTH AFRICA ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 281. SOUTH AFRICA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
TABLE 282. SPAIN ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 283. SPAIN ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 284. SPAIN ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
TABLE 285. SPAIN ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 286. SPAIN ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
TABLE 287. SPAIN ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 288. SPAIN ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
TABLE 289. SWEDEN ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 290. SWEDEN ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 291. SWEDEN ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
TABLE 292. SWEDEN ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 293. SWEDEN ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
TABLE 294. SWEDEN ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 295. SWEDEN ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
TABLE 296. SWITZERLAND ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 297. SWITZERLAND ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 298. SWITZERLAND ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
TABLE 299. SWITZERLAND ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 300. SWITZERLAND ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
TABLE 301. SWITZERLAND ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 302. SWITZERLAND ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
TABLE 303. TURKEY ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 304. TURKEY ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 305. TURKEY ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
TABLE 306. TURKEY ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 307. TURKEY ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
TABLE 308. TURKEY ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 309. TURKEY ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
TABLE 310. UNITED ARAB EMIRATES ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 311. UNITED ARAB EMIRATES ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 312. UNITED ARAB EMIRATES ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
TABLE 313. UNITED ARAB EMIRATES ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 314. UNITED ARAB EMIRATES ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
TABLE 315. UNITED ARAB EMIRATES ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 316. UNITED ARAB EMIRATES ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
TABLE 317. UNITED KINGDOM ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 318. UNITED KINGDOM ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 319. UNITED KINGDOM ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
TABLE 320. UNITED KINGDOM ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 321. UNITED KINGDOM ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
TABLE 322. UNITED KINGDOM ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 323. UNITED KINGDOM ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
TABLE 324. ANOREXIA NERVOSA MARKET SHARE, BY KEY PLAYER, 2023
TABLE 325. ANOREXIA NERVOSA MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Anorexia Nervosa Market, which are profiled in this report, include:
  • Alkermes plc
  • Amgen Inc.
  • Biohaven Pharmaceuticals
  • Hologic, Inc.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Mindstrong Health
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • PsychoGenics Inc.
  • Sanofi S.A.
  • Sumitomo Pharma America, Inc.
  • Takeda Pharmaceutical Company Limited.
  • Tonix Pharmaceuticals Holding Corp.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages194
PublishedOctober 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 106.87 Million
Forecasted Market Value ( USD ) by 2030 $ 226.52 Million
Compound Annual Growth Rate13.2%
Regions CoveredGlobal
No. of Companies Mentioned15

Related Topics

Related Reports

Anorexia Nervosa - Pipeline Insight, 2024 - Product Image

Anorexia Nervosa - Pipeline Insight, 2024

  • Clinical Trials
  • 60 Pages
  • Global
From
Global Mental Health and Psychotherapy. Adapting Psychotherapy for Low- and Middle-Income Countries. Global Mental Health in Practice - Product Image

Global Mental Health and Psychotherapy. Adapting Psychotherapy for Low- and Middle-Income Countries. Global Mental Health in Practice

  • Book
  • Global
An Evolutionary Approach to Understanding and Treating Anorexia Nervosa and Other Eating Problems - Product Image

An Evolutionary Approach to Understanding and Treating Anorexia Nervosa and Other Eating Problems

  • Book
Eating Disorder Clinics in the US - Industry Market Research Report - Product Image

Eating Disorder Clinics in the US - Industry Market Research Report

  • Report
  • 73 Pages
  • United States
From
Eating Disorders: Part I, An Issue of Psychiatric Clinics of North America. The Clinics: Internal Medicine Volume 42-1 - Product Image

Eating Disorders: Part I, An Issue of Psychiatric Clinics of North America. The Clinics: Internal Medicine Volume 42-1

  • Book
  • North America

About the Anorexia Market

Anorexia is a mental health disorder characterized by an extreme fear of gaining weight and an intense desire to be thin. It is often accompanied by an unhealthy preoccupation with food, body image, and weight. People with anorexia may restrict their food intake, exercise excessively, or use other unhealthy methods to lose weight. Anorexia can have serious physical and psychological consequences, including malnutrition, organ damage, and depression. The anorexia market is a subset of the mental health market, which is estimated to be worth billions of dollars. It is a growing market, with an increasing number of companies offering treatments and services for people with anorexia. These companies provide a range of services, including counseling, nutrition education, and support groups. Some companies in the anorexia market include Eating Recovery Center, The Emily Program, and The Renfrew Center. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.